Deniz Ceyda Bakırlı

Deniz Ceyda Bakırlı

Auto-generated profile, based on publicly available information

Deniz Ceyda Bakırlı

Department of Pharmacology and Toxicology Izmir Kâtip Celebi University Faculty of Medicine Izmir Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

6 May 2026 in Breastfeeding Medicine
Verified
Journal Article
Closed access
BEBurak Eskiyurt
Burak Eskiyurt
EHErsan Horoz
Ersan Horoz
DBDeniz Ceyda Bakırlı
Deniz Ceyda Bakırlı
MGMesut Gungor
Mesut Gungor
BKBaris Karadas
Baris Karadas
YKYusuf Cem Kaplan
Yusuf Cem Kaplan
Background: Etanercept is a tumor necrosis factor inhibitor frequently used to control ankylosing spondylitis (AS) in women of reproductive age, yet data on its safety during breastfeeding are limited. We report a case of an infant who developed somnolence, hypotonia, feeding difficulties, and a concomitant infection temporally associated with maternal etanercept therapy during lactation and discuss implications for breastfeeding. Case: A 33-year-old woman with AS delivered a healthy female infant by cesarean section at 36 + 5 weeks’ gestation and began exclusive breastfeeding. At 11 weeks postpartum, she initiated etanercept 25 mg subcutaneously once weekly for her active disease. During treatment, the infant developed prolonged sleep, somnolence, feeding difficulty, and hypotonia, followed within a week by low-grade fever, cough, and nasal congestion. After three doses, etanercept was discontinued, and she was referred to our teratology information service. Approximately 2 weeks after the last dose, the infant’s respiratory symptoms worsened, and diarrhea developed, prompting emergency admission. Laboratory evaluation showed leukocytosis, elevated C-reactive protein, and a nasopharyngeal swab, which was positive for rhinovirus/enterovirus. Symptoms resolved with supportive care and azithromycin by treatment days 4–5. At 9 months of age, the infant has had no other health issues. Conclusions: This case illustrates the difficulty of interpreting adverse events in breastfed infants exposed to maternal biologic medications. Although current evidence suggests no clinically severe adverse effects, minimal infant exposure, and a low risk of clinically relevant immunosuppression with etanercept during breastfeeding, individualized counseling and careful monitoring of exposed infants remain essential.

30 June 2026 in The New Journal of Urology
Verified
Journal Article
Open access
DBDeniz Ceyda Bakırlı
Deniz Ceyda Bakırlı
EHErsan Horoz
Ersan Horoz
IYIsmail Yilmaz
Ismail Yilmaz
YIYusuf Özlem İlBey
Yusuf Özlem İlBey
Objective : This narrative review evaluates current evidence regarding the impact of paternal selective serotonin reuptake inhibitor (SSRI) use on male fertility parameters and neonatal outcomes. Material and Methods: A comprehensive search of PubMed/MEDLINE and Web of Science databases was conducted for studies published up to December 2025. Out of 132 screened records, 13 studies investigating common SSRIs (e.g., sertraline, citalopram, escitalopram, fluoxetine, paroxetine, fluvoxamine) and newer agents (vortioxetine, vilazodone) were included in the narrative synthesis. Results: Evidence indicates that SSRIs may cause transient impairments in sperm motility, morphology, and DNA integrity, which are generally reversible following treatment discontinuation. Large-scale cohort studies demonstrate no significant association between paternal SSRI use and major congenital malformations, low Apgar scores, or small-for-gestational-age (SGA) births. While a modest increase in preterm birth risk was noted, this is likely attributable to confounding by the underlying paternal psychiatric condition rather than direct pharmacological exposure. Similarly, associations with neurodevelopmental outcomes, such as Autism Spectrum Disorder (ASD) and Attention Deficit/Hyperactivity Disorder (ADHD), are more likely explained by paternal psychiatric conditions rather than direct drug exposure. Conclusion: Paternal SSRI use does not appear to pose a significant risk to clinical fertility or offspring health. Given the transient nature of semen abnormalities, treatment should be tailored individually to balance psychiatric stability and reproductive goals.

1 November 2026 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
DBDeniz Ceyda Bakirli
Deniz Ceyda Bakirli
EHErsan Horoz
Ersan Horoz
CKCagri Caglayan Kuragi
Cagri Caglayan Kuragi
MGMesut Gungor
Mesut Gungor
OKOsman Karakulak
Osman Karakulak
YKYusuf Cem Kaplan
Yusuf Cem Kaplan